News By Tag
News By Place
Follow on Google News
p53 Prions - Novel Biomarker for Circulating Tumor Cells
Patent-pending Test Kit by OncoLab Launched. Novel tests by OncoLab (Austria) identify cancer cells via p53 prions.
By: OncoLab Diagnostics GmbH
- Novel tests by OncoLab (Austria) identify cancer cells via p53 prions
- Kits for use with tissues, cells, and blood available
- OncoLab's range of IF and PCR-based circulating rare cell (CRC) detection kits extended
Wiener Neustadt (Austria), September 22nd, 2021. A patent-pending new technology allows more reliable identification of circulating tumor cells (CTC). The technology is based on the identification of p53 aggregates ("p53 prions") using Blood-based Biopsy tests (BBB) developed by OncoLab GmbH, Austria. p53 is a well-known tumor suppressor protein. Mutations of the gene can cause prion-like aggregation of p53-proteins. OncoLab has developed tests for amplified immuno-labeling of these aggregates using proprietary technology of Navinci Diagnostics AB, the Swedish specialist for visualizing proteins and their protein-protein interactions and post-translational modifications.
Besides p53 aggregates the OncoLab's CTC test "nPACTM AMYLOplexTM CTC-p53" also detects known CTC markers (several cytokeratins)
About OncoLab Diagnostics GmbH (September 2021)
OncoLab develops, manufactures and distributes innovative and precise diagnostic tests with a focus on Blood-based Biopsy tests. Products are available for detecting circulating tumor, endothelial and stromal cells as well as immune cells. The company is certified according to ISO 9001:2015 and ISO 13485:2016 and member of the International Society of Liquid Biopsy (ISLB) and the European Liquid Biopsy Society (ELBS).